A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects
Latest Information Update: 26 Feb 2025
At a glance
- Drugs HS 20094 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 26 Feb 2025 New trial record